Customers looking for an mRNA therapeutic partner should prioritize operational excellence and choose flexible CDMOs.
A new study in the journal Human Gene Therapy indicates that DNA impurities derived from plasmid and host cell DNA are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback